CTLA4 and melanoma: In particular, inhibitors of the cytoplasmic serine/threonine kinase BRAF and the immune-checkpoint targeted agents, anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), and anti-programmed cell death 1 (PD-1) inhibitors have been approved for the treatment of advanced melanoma.